Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs has been granted Orphan Drug Designation by the FDA for its drug candidate SL-172154, which is being developed for the treatment of Acute Myeloid Leukemia.
June 10, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs has been granted Orphan Drug Designation by the FDA for its drug candidate SL-172154, which is being developed for the treatment of Acute Myeloid Leukemia. This designation can provide benefits such as market exclusivity, tax credits, and assistance in the drug development process.
The FDA's Orphan Drug Designation is a significant milestone for Shattuck Labs as it can lead to market exclusivity, tax credits, and other benefits that can accelerate the development and potential commercialization of SL-172154. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100